A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors Y-mAbs Therapeutics
- 08 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
- 13 Oct 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.
- 11 Sep 2017 New trial record